Aberdeen Group plc Grows Stock Holdings in Immunic, Inc. $IMUX

by · The Markets Daily

Aberdeen Group plc raised its stake in Immunic, Inc. (NASDAQ:IMUX – Free Report) by 678.1% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 8,243,941 shares of the company’s stock after buying an additional 7,184,457 shares during the period. Aberdeen Group plc owned about 0.09% of Immunic worth $5,750,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently added to or reduced their stakes in the company. Focus Partners Wealth boosted its position in Immunic by 19.1% in the 1st quarter. Focus Partners Wealth now owns 2,583,457 shares of the company’s stock valued at $2,816,000 after buying an additional 415,104 shares during the period. 683 Capital Management LLC boosted its position in Immunic by 28.6% in the 1st quarter. 683 Capital Management LLC now owns 900,000 shares of the company’s stock valued at $981,000 after buying an additional 200,000 shares during the period. Finally, Jane Street Group LLC boosted its position in Immunic by 279.3% in the 1st quarter. Jane Street Group LLC now owns 207,401 shares of the company’s stock valued at $226,000 after buying an additional 152,726 shares during the period. 51.82% of the stock is owned by hedge funds and other institutional investors.

Immunic Stock Down 2.6%

NASDAQ IMUX opened at $0.82 on Friday. The firm has a market cap of $80.49 million, a PE ratio of -0.87 and a beta of 1.56. The company has a 50 day moving average price of $0.87 and a 200 day moving average price of $0.90. Immunic, Inc. has a 52 week low of $0.56 and a 52 week high of $1.73.

Immunic (NASDAQ:IMUX – Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.02). On average, equities research analysts anticipate that Immunic, Inc. will post -0.94 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on IMUX. Chardan Capital started coverage on shares of Immunic in a research report on Monday, September 29th. They issued a “buy” rating and a $13.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price target on shares of Immunic in a research report on Friday, September 26th. D. Boral Capital reaffirmed a “buy” rating and issued a $10.00 price target on shares of Immunic in a research report on Thursday, September 25th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immunic in a research report on Wednesday, October 8th. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $9.50.

Get Our Latest Analysis on IMUX

About Immunic

(Free Report)

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.

Further Reading

Want to see what other hedge funds are holding IMUX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Immunic, Inc. (NASDAQ:IMUX – Free Report).